November I, 2024

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

“We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future."

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to target the BCR-ABL fusion in chronic myelogenous leukemia.

Oncology trials often celebrate treatments improving progression-free survival, yet toxicity-related censoring can bias results. Emphasizing overall survival and quality of life offers clearer insights into true clinical benefit.